Abstracts tagged "giant cell arteritis"

Abstract Number: 0503 • ACR Convergence 2021
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Kaitlin Quinn¹, Mark A. Ahlman², Hugh Alessi³, Ashkan Malayeri², Jamie Marko², Elaine Novakovich² and Peter Grayson⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
Abstract Number: 1403 • ACR Convergence 2021
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
Eugenio De Miguel¹, Jesús T. Sánchez-Costa², Javier Narvaez³, Miguel Ángel gonzalez-Gay⁴, Noemí Garrido-Puñal⁵, Paula V. Estrada-Alarcon⁶, Rafael B. Melero-González⁷, Elisa Fernández-Fernández⁸, María T. Silva-Diaz⁹, Joaquín M. Belzunegui¹⁰, Clara Moriano¹¹, Julio Sánchez¹², Judit Lluch¹³, Itziar Calvo¹⁴, Vicente Aldasoro¹⁵, Leticia León-Mateos¹⁶, Javier Loricera García¹⁷, Alberto Ruíz-Román⁵, Cristina Valero-Martínez¹⁸, Patricia Moya¹⁹, Marina Tortosa-Cabañas²⁰, Vanessa A. Navarro-Angeles⁶, Carles Galisteo²¹, Anne Riveros-Frutos²², Jose A. Román-Ivorra²³, Selene Labrada-Arrabal²⁴, Margarida Vasques-Rocha²⁵, Carlota L. Iñiguez-Ubiaga²⁶, María García-González²⁷ and Ricardo Blanco²⁸, ¹Hospital Universitario La Paz, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁶Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁹Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ¹⁰Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ¹¹Hospital Universitario de León, León, Spain, ¹²Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁶Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁸Hospital Universitario de La Princesa, Madrid, Spain, ¹⁹Hospital Sant Pau, Barcelona, Spain, ²⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ²¹Hospital Universitari Parc Tauli, Saadell, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁴Hospital del Mar, Barcelona, Spain, ²⁵Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁷Hospital Universitario de Canarias, La Laguna, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis over 50 years of age. Classically, GCA was assimilated with the involvement of the…
Abstract Number: 1859 • ACR Convergence 2021
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Adam Geressu¹ and Marwan Bukhari², ¹Royal Lancaster Infirmary, Lancaster, United Kingdom, ²British Society for Rheumatology, London, United Kingdom
Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
Abstract Number: 0505 • ACR Convergence 2021
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Despina Michailidou¹, Tianyu Zhang², Pavlos Stamatis³ and Bernard Ng⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
Abstract Number: 1404 • ACR Convergence 2021
Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis; A Population-based Study
jigisha rakholiya¹, Mohanad Elfishawi¹, Tina Gunderson¹, Cynthia Crowson², Eric Matteson³, Carl Turesson⁴, Karin Wadström⁵, Cornelia Weyand¹, Matthew Koster¹ and Kenneth Warrington⁶, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Lund University, Malm, Sweden, ⁵Lund University, Malmö, Sweden, ⁶Mayo Clinic, Rochester, Minnesota
Background/Purpose: Advancing age, female sex and white race are well-known risk factors for development of giant cell arteritis (GCA). Recent studies suggest that certain metabolic…
Abstract Number: 1862 • ACR Convergence 2021
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Kristina Wells¹, Fernanda Gutierrez-Rodrigues², Bhavisha Patel², Kaitlin Quinn³, Keith Sikora¹, Neal Young⁴ and Peter Grayson⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institues of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…
Abstract Number: 0506 • ACR Convergence 2021
Transcriptomic Changes Induced by Mavrilimumab versus Tocilizumab in ex-vivo Cultured Arteries from Patients with Giant-cell Arteritis
Marc Corbera- Bellalta¹, Farah Kamberovic¹, Farran Araujo², Roser Alba-Rovira¹, Georgina Espigol-Frigolé¹, Marco A. Alba¹, Sergio Prieto-Gonzalez¹, José Hernández-Rodríguez¹, Patricia Pérez-Galán², Alexandra Joseph³, John F Paolini³ and Maria C. Cid¹, ¹Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, ²Department of Hemato-Oncology (IDIBAPS), Barcelona, Spain, ³Kiniksa Pharmaceuticals Corp., Lexington, MA
Background/Purpose: Giant cell arteritis (GCA) is a chronic disease, and affected patients suffer from relapses and glucocorticoid (GC)-related toxicity. Targeted therapies are emerging with the…
Abstract Number: 1405 • ACR Convergence 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Lara Sánchez-Bilbao¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, Javier Narvaez⁴, Vicente Aldasoro⁵, Olga Maíz⁶, Rafael Melero⁷, Juan Ignacio Villa⁸, Paloma Vela⁹, Susana Romero-Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesús Carlos Fernández-López¹⁵, Carles Galisteo¹⁶, Iván Ferraz-Amaro¹⁷, Juan Carlos Nieto¹⁸, Juan Ramón de Dios¹⁹, Julio Sánchez²⁰, Esther Fernández²¹, Isabel de la Morena²², Patricia Moya²³, Roser Solans-Laqué²⁴, Jose Luis Andreu²⁵, Marcelino Revenga²⁶, Eztizen Labrador²⁷, Andrea García-Valle²⁸, Adela Gallego²⁹, Carlota Iñíguez³⁰, Cristina Hidalgo³¹, Noemí Garrido-Puñal³², Ruth López-González³³, José Andrés Román-Ivorra³⁴, Sara Manrique Arija³⁵, Paz Collado³⁶, Enrique Raya¹¹, Francisco Navarro³⁷, Antoni Juan Mas³⁸, Carmen Ordas³⁹, Maria Dolors Boquet⁴⁰, Noelia Álvarez-Rivas⁴¹, Maria Luisa Velloso-Feijoo⁴², Cristina Campos-Fernández⁴³, Íñigo Rúa-Figueroa⁴⁴, Arantxa Conesa⁴⁵, Eva Salgado⁴⁶, Miguel Ángel gonzalez-Gay⁴⁷ and Ricardo Blanco⁴⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario de la Princesa, Madrid, Spain, ³Hospital Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁸Hospital Sierrallana, Torrelavega, Spain, ⁹Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ¹⁶Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁹Hospital Universitario de Araba, Mondragón, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²²Hospital Clínico Universitario de Valencia, Valencia, Spain, ²³Hospital Sant Pau, Barcelona, Spain, ²⁴Hospital Vall d'Hebron, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Hospital San Pedro, Logroño, La Rioja, Spain, ²⁸Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, ²⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ³⁰Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³³Complejo Hospitalario de Zamora, Zamora, Spain, ³⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³⁵Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ³⁶Hospital Universitario Severo Ochoa, Madrid, Spain, ³⁷Hospital General Universitario de Elche, Elche, Spain, ³⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ³⁹Hospital de Cabueñes, Gijón, Spain, ⁴⁰Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, ⁴¹Hospital San Agustín, Aviles, Spain, ⁴²Hospital Universitario de Valme, Sevilla, Spain, ⁴³Consorci Hospital General Universitari de Valencia, Valencia, Spain, ⁴⁴Hospital Universitario Doctor Negrín, Gran Canaria, Spain, ⁴⁵Hospital Universitario de Castellón, Castellón, Spain, ⁴⁶Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) may be divided into cranial, and extracranial GCA phenotypes. Tocilizumab (TCZ) has shown efficacy and safety in GCA.Our aim was…
Abstract Number: 1864 • ACR Convergence 2021
18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis
Ertugrul Cagri bolek¹, Kaitlin Quinn², Hugh Alessi³, Elaine Novakovich⁴, Mark A. Ahlman⁴ and Peter Grayson⁵, ¹Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Imaging modalities play an important role in the diagnosis and management of patients with large-vessel vasculitis (LVV). Use of 18F-fluorodeoxyglucose (FDG) positron emission tomography…
Abstract Number: L06 • ACR Convergence 2020
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Maria C. Cid¹, Sebastian Unizony², Lara Pupim³, Fang Fang⁴, Joseph Pirrello³, Ai Ren⁴, Manoj Samant⁴, Teresa Zhou⁴ and John F Paolini⁴, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Massachusetts General Hospital, Boston, MA, ³Kiniksa Pharmaceuticals, Lexington, MA, ⁴Kiniksa Pharmaceuticals, Lexington
Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
Abstract Number: 0513 • ACR Convergence 2020
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
Sebastian Unizony¹, Robert Morris², Johannes Kreuzer², Wilhelm Haas² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…
Abstract Number: 1923 • ACR Convergence 2020
Angiographic Progression of Disease in Large-Vessel Vasculitis
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Angiography is essential to detect vascular disease in patients with large-vessel vasculitis (LVV). Guidelines differ on the role of periodic angiography to monitor patients…
Abstract Number: 1941 • ACR Convergence 2020
Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events
Shu Cao¹, Caroline Bresnan², Si Li³, Yichen Wang³ and Yih Chang Lin¹, ¹University of South Florida, Morsani College of Medicine, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, ³The Wright Center for Graduate Medical Education, Scranton
Background/Purpose: Giant cell arteritis (GCA) has been shown to have an increased risk of developing deep venous thrombosis (DVT), pulmonary embolism (PE) and combined thromboembolism…
Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 1924 • ACR Convergence 2020
Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
John H. Stone¹, Navita L. Mallalieu² and Min Bao³, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Innovation Center, New York, NY, ³Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) has low immunogenicity in patients with rheumatoid arthritis (RA).1 The risk for TCZ immunogenicity remains to be determined in patients with giant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].